Your browser doesn't support javascript.
loading
Prognostic significance of axillary dissection in breast cancer patients with micrometastases or isolated tumor cells in sentinel nodes: a nationwide study.
Tvedskov, Tove Filtenborg; Jensen, Maj-Britt; Ejlertsen, Bent; Christiansen, Peer; Balslev, Eva; Kroman, Niels.
Afiliação
  • Tvedskov TF; Department of Breast Surgery, Copenhagen University Hospital, Afs 4124, Rigshospitalet, Blegdamsvej 9, 2100 København Ø, Copenhagen, Denmark. tft@dadlnet.dk.
  • Jensen MB; Danish Breast Cancer Cooperative Group, Copenhagen University Hospital, Copenhagen, Denmark.
  • Ejlertsen B; Department of Clinical Oncology and Danish Breast Cancer Cooperative Group, Copenhagen University Hospital, Copenhagen, Denmark.
  • Christiansen P; Breast Surgery Unit, Department of Surgery, Aarhus University Hospital/Randers Regional Hospital, Aarhus, Denmark.
  • Balslev E; Department of Pathology, Herlev Hospital, Copenhagen, Denmark.
  • Kroman N; Department of Breast Surgery, Copenhagen University Hospital, Afs 4124, Rigshospitalet, Blegdamsvej 9, 2100 København Ø, Copenhagen, Denmark.
Breast Cancer Res Treat ; 153(3): 599-606, 2015 Oct.
Article em En | MEDLINE | ID: mdl-26341752
ABSTRACT
We estimated the impact of axillary lymph node dissection (ALND) on the risk of axillary recurrence (AR) and overall survival (OS) in breast cancer patients with micrometastases or isolated tumor cells (ITC) in sentinel nodes. We used the Danish Breast Cancer Cooperative Group (DBCG) database to identify patients with micrometastases or ITC in sentinel nodes following surgery for primary breast cancer between 2002 and 2008. A Cox proportional hazard regression model was developed to assess the hazard ratios (HR) for AR and OS between patients with and without ALND. We identified 2074 patients, of which 240 did not undergo further axillary surgery. The 5-year cumulated incidence for AR was 1.58 %. No significant difference in AR was seen between patients with and without ALND. The age adjusted HR for AR if ALND was omitted was 1.79 (95 % CI 0.41-7.80, P = 0.44) in patients with micrometastases and 2.21 (95 % CI 0.54-8.95, P = 0.27), in patients with ITC after a median follow-up of 6 years and 3 months. There was no significant difference in overall survival between patients with and without ALND, when adjusting for age, co-morbidity, tumor size, histology type, malignancy grade, lymphovascular invasion, hormone receptor status, adjuvant systemic treatment and radiotherapy, with a HR for death if ALND was omitted of 1.21 (95 % CI 0.86-1.69, P = 0.27) in patients with micrometastases and 0.96 (95 % CI 0.57-1.62, P = 0.89) in patients with ITC after a medium follow-up on 8 and 5 years. In this nationwide study, we found a low risk of AR on 1.58 % and we did not find a significantly increased risk of AR if ALND was omitted in patients with micrometastases or ITC in sentinel nodes. Furthermore, no significant difference in overall survival was seen between patients with and without ALND when adjusting for adjuvant treatment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Axila / Neoplasias da Mama / Biópsia de Linfonodo Sentinela / Linfonodos Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged País/Região como assunto: Europa Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Dinamarca

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Axila / Neoplasias da Mama / Biópsia de Linfonodo Sentinela / Linfonodos Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged País/Região como assunto: Europa Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Dinamarca